Immoculation SRL
1.0 FTEThe score of Immoculation shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +60 % Total assets +107 % Headcount (avg FTE) 0 %
Accounts of the company itself (not consolidated).
The full file covers 8 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Immoculation's annual accounts
Filed annual accounts
- Year ended 30 Jun 2025filed on 28 Jan 2026
- Year ended 30 Jun 2024filed on 17 Dec 2024
- Year ended 30 Jun 2023filed on 10 Jan 2024
- Year ended 30 Jun 2022filed on 21 Dec 2022
- Year ended 30 Jun 2021filed on 07 Jan 2022
Immoculation's financial analysis
- Solvency16.0%sector median: 44.0%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Immoculation
Immoculation's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0458.161.385
- VAT number
- BE0458161385
- Peppol
- Registered · 0208:0458161385 · as of 04 Nov 2026
- Legal form
- SRL
- Incorporated
- 13 Jun 1996
- Registered office
- 9880 Aalter
- Size
- Micro · 1.0 FTE
- Latest accounts
- 2025 · filed on 28 Jan 2026
- Activity
- Rental and operating of own or leased residential real estate, except social housing (NACE 68201)
Immoculation (SRL) has been based in Aalter since 1996, active in: rental and operating of own or leased residential real estate, except social housing. For 2025, it reports a net loss of 69,360 € and equity of 463,763 €; its revenue is not published. With 1.0 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at 16.0%, below the median of its sector (44.0%).
Companies similar to Immoculation
Companies in the same business, of comparable size and area, outside its group.
- Atos Europe Other business support service activities n.e.c. Ghent · balance sheet €3.15m
- Linnaeus Business and other management consultancy activities Lochristi · balance sheet €2.57m
- That'S IT Other business support service activities n.e.c. Destelbergen · balance sheet €2.02m
- Nexus Investments Business and other management consultancy activities Knokke-Heist · balance sheet €1.50m
- Group Invist Business and other management consultancy activities Antwerp · balance sheet €10.1m
- Better Keep Cool Business and other management consultancy activities Uccle · balance sheet €1.03m
- LMSA Business and other management consultancy activities Tournai · balance sheet €9.65m
- Green4You Other business support service activities n.e.c. Saint-Josse-ten-Noode · balance sheet €16.2m
Frequently asked questions about Immoculation
What is the revenue of Immoculation?
Immoculation files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Immoculation?
In Belgium, the VAT number is the company number prefixed with BE: BE0458161385 for Immoculation, if the company is VAT-registered. Its company number (CBE) is 0458.161.385.
Where is the registered office of Immoculation?
According to the CBE register, the registered office of Immoculation is in 9880 Aalter.
What is the equity of Immoculation?
At the close of the 2025 financial year, the equity of Immoculation amounts to 463,763 €, a solvency of 16.0% of total assets.
How many people work at Immoculation?
1.0 full-time equivalents on average according to the 2025 social balance sheet.
Who manages Immoculation?
The register lists 2 active mandates at Immoculation. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Immoculation
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →